Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
D. Lorusso, Nicoletta Colombo, Coraline Dubot, M.V. Cáceres, Kazuki Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, A. Arkhipov, Ka Wan Li, S. Toker, C. Tekin, Krishnansu S. Tewari, B.J. Monk
Topics & Concepts
MedicineBevacizumabPembrolizumabInternal medicineOncologyChemotherapyHazard ratioResponse Evaluation Criteria in Solid TumorsSurgeryCancerProgressive diseaseImmunotherapyConfidence intervalEndometrial and Cervical Cancer TreatmentsColorectal and Anal CarcinomasNatural Compounds in Disease Treatment